James Chapman is a Cardiology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
900 E 13th St
Suite 200
Grove, OK 743442975
Telephone
918-592-0999Registry record last updated 31 Dec 2014.
Clinical trials
- Clinical Evaluation of the CADenceTM System in Detection of Coronary Artery Diseases
Sponsor: AUM Cardiovascular, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
19 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year202511 payments
- ABIOMEDProgram year20257 payments
- Kestra Medical Technology Services, Inc.Program year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
80.9%Beta blocker27.1%Metoprolol Succinate63%Metoprolol Tartrate16%Carvedilol15%Nebivolol Hcl4%Atenolol2%Part D<11 patientsStatin10.5%Atorvastatin Calcium66%Rosuvastatin Calcium30%Pravastatin Sodium4%Part D<11 patients+ 15 more classes in this area
Blood & clotting
17.3%Factor Xa inhibitor11.1%Eliquis95%Xarelto6%Part D<11 patientsP2Y12 inhibitor5.1%Clopidogrel100%Part D≥63 patients+ 1 more class in this area
Metabolism & gastrointestinal
1.8%Proton pump inhibitor1.1%Pantoprazole Sodium67%Omeprazole33%Part D<11 patientsPotassium supplement0.7%Potassium Chloride100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”